Wednesday, May 31, 2023
  • Login
CEO North America
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
  • Home
  • Business
    • Entrepreneur
    • Industry
    • Innovation
    • Management & Leadership
  • CEO Interviews
  • CEO Life
    • Art & Culture
    • Food
    • Health
    • Travel
    • Environment
  • Opinion
  • News
  • Multimedia
No Result
View All Result
CEO North America
No Result
View All Result

Pfizer Partners with Tiny Biotech to Research Next-Gen Covid Treatment

in News, Uncategorized
Pfizer partners with tiny biotech to research next-gen covid treatment
Share on LinkedinShare on WhatsApp

On December 6th, Pfizer (NYSE: PFE) announced a research collaboration and exclusive license agreement with Clear Creek Bio — a 10-person biotech that has an office in Cambridge, MA, but operates fully remotely. This program will expand Pfizer’s innovative anti-infective pipeline and, if successful, will complement Pfizer’s existing portfolio of COVID-19 products with direct-acting antiviral agents against different SARS-CoV-2 targets.

“COVID-19 has proven to be a devastating and highly unpredictable disease, one with the potential to remain a global health concern for years to come,” said Charlotte Allerton, Chief Scientific Officer, Anti-Infectives and Head of Medicine Design, of Pfizer. “It is critical that we try to stay ahead of the virus, continuing to advance clinical development opportunities for our current oral therapy as well as innovating through our internal programs and strategic partnerships to bring forward additional monotherapy and/or combination treatment candidates that we believe may play a role in the ongoing fight against COVID-19.”

Under the terms of the agreement, the two companies will work together to identify an essential enzyme (PLpro), which plays an important role in viral replication. At which time Pfizer will be solely responsible for further development and commercialization activities. Clear Creek Bio will receive an undisclosed upfront payment and will be eligible to receive additional potential milestone payments plus royalties on future product sales.

Tags: Biotech industryCOVID-19Pfizer

Related Posts

Glencore to make bigger offer for canada’s teck resources
News

Glencore to make bigger offer for Canada’s Teck Resources

Former coinbase manager, brother settle sec insider-trading charges
News

Former Coinbase manager, brother settle SEC insider-trading charges

Ai means anybody can be a programmer, nvidia’s ceo says
News

Nvidia becomes first chipmaker valued at $1 trillion

Biden raises debt ceiling
News

Biden, McCarthy reach US debt-ceiling deal

Yellen warns on big economic repercussions in ukraine and beyond
News

US debt-ceiling deadline extended to June 5

The missing workers who are never coming back
News

Office REITs hit lowest level since 2009 amid remote work, tighter budgets

Cisco warns ai software could make phishing attacks harder to fend off
News

OpenAI raises $175m startup investment fund

Blackstone in talks to buy us regional banks’ assets
News

Blackstone in talks to buy US regional banks’ assets

- citi abandons banamex sale, plans ipo instead
News

Citi abandons Banamex sale, plans IPO instead

Whatsapp to add message-editing feature
News

WhatsApp to add message-editing feature

No Result
View All Result

Recent Posts

  • Glencore to make bigger offer for Canada’s Teck Resources
  • Former Coinbase manager, brother settle SEC insider-trading charges
  • AI will require more power than just the cloud
  • Nvidia becomes first chipmaker valued at $1 trillion
  • Biden, McCarthy reach US debt-ceiling deal

Recent Comments

    Archives

    Categories

    • Art & Culture
    • Business
    • CEO Interviews
    • CEO Life
    • Editor´s Choice
    • Entrepreneur
    • Environment
    • Food
    • Health
    • Highlights
    • Industry
    • Innovation
    • Issues
    • Management & Leadership
    • Multimedia
    • News
    • Opinion
    • PrimeZone
    • Printed Version
    • Travel
    • Uncategorized

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials – stuart.james@ceo-na.com

    Advertising – media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

     

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    • CONTACT
    • GENERAL ENQUIRIES
    • ADVERTISING
    • MEDIA KIT
    • DIRECTORY
    • TERMS AND CONDITIONS

    Editorials –
    stuart.james@ceo-na.com

    Editor-In-Chief –

    caroline.sposto@ceo-na.com

    Editorials – editorials@ceo-na.com

    Advertising –
    media@ceo-na.com

    NEW YORK

    110 Wall St.,
    3rd Floor
    New York, NY.
    10005
    USA
    +1 212 432 5800

    MEXICO CITY

    Paseo de la Reforma 296,
    Floor 38
    Mexico City
    06600
    MEXICO

    CEO North America © 2022 - Sitemap

    No Result
    View All Result
    • Home
    • Business
      • Entrepreneur
      • Industry
      • Innovation
      • Management & Leadership
    • CEO Interviews
    • CEO Life
      • Art & Culture
      • Food
      • Health
      • Travel
      • Environment
    • Opinion
    • News
    • Multimedia

    © 2023 JNews - Premium WordPress news & magazine theme by Jegtheme.

    Welcome Back!

    Login to your account below

    Forgotten Password?

    Retrieve your password

    Please enter your username or email address to reset your password.

    Log In

    Warning: array_sum() expects parameter 1 to be array, null given in /home/ceonacom/public_html/wp-content/plugins/jnews-social-share/class.jnews-social-background-process.php on line 111